Contrave sales seem to be flattening out. The drug's gains in market share are slowing. Peak sales of Contrave in 2016 may already have passed. Orexigen (NASDAQ:OREX) investors have a lot on their ...

The MarketWatch News Department was not involved in the creation of this content. Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan ...

Data to be shared during an ObesityWeek press conference include four of seven presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Nov. 4, 2025 ...

Forbes contributors publish independent expert analyses and insights. I report the latest in health, nutrition, wellness and healthy travel. Will the FDA finally approve Contrave, Orexigen’s hot new ...

Arena and Vivus fell flat with their obesity drugs, but will Orexigen suffer the same fate? What is Contrave? Contrave combines the previously approved drugs naltrexone and bupropion. Naltrexone is ...

- 62% of the Patients Completing Trial on Contrave32 Lost at Least 5% of Body Weight Compared to 23% of Patients on Placebo - Patients Taking Contrave(R) Also Showed Significant Improvement in Markers ...

Contrave sales were flat last week and dipped this week. Competitor lowered price two weeks ago. What can help Contrave win back scripts? Orexigen (OREX) investors saw the second week of script ...

A weight-loss drug called Contrave may be approved by the Food and Drug Administration in the coming weeks if the agency follows the advice of one of its panels, which recently weighed in on the ...

Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan (FEP) BRENTWOOD, Tenn., Oct. 23, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC, a ...

When compared to placebo, patients treated with CONTRAVE showed significant improvements in positive mood, reduced cravings for savory foods, and overall greater control of cravings. The study further ...